VALCHLOR—made specifically to treat MF-CTCL

The first and only FDA-approved mechlorethamine gel

MF-CTCL is defined as mycosis fungoides-type cutaneous T-cell lymphoma. Cutaneous means relating to or affecting the skin.

Actor portrayal.

Treats MF-CTCL by destroying rapidly growing T-cells

Topical, once-daily application at home

Acts directly on the skin and does not enter the bloodstream

VALCHLOR is a topical gel medication that treats patients with Stage IA/IB MF-CTCL who have received previous skin treatment. Ask your doctor if VALCHLOR is right for you.

Actor portrayal.